← Human Trials & Peer-Reviewed Studies
GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
Plain-language guide to PMID 32518064 (2020): double-blind randomized controlled trial of GIP (Gastric Inhibitory Polypeptide) in 10 subjects.
Key Facts
- PMID
- 32518064
- Journal
- Diabetes
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Christensen AS et al. (9 authors)
- DOI
- 10.2337/db20-0074
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at GIP (Gastric Inhibitory Polypeptide).
Treatment based on the incretin hormones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1) is characterized by their glucose-dependent insulinotropic actions without risk of hypoglycemia.
The effect of SUs together with GIP or GLP-1, respectively, on insulin and glucagon secretion in patients with HNF1A diabetes is currently unknown.
Who Took Part
The abstract describes 10 subjects taking part.
By PubMed's age tags, the people studied were adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
The subjects were allocated by chance, so the GIP (Gastric Inhibitory Polypeptide) group and the comparison group should start out alike.
Blinding on both sides kept the subjects and researchers unaware of who received GIP (Gastric Inhibitory Polypeptide).
The comparison arm used a placebo, so changes seen with GIP (Gastric Inhibitory Polypeptide) could be set against what happens without it.
In the crossover set-up each of the subjects took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.
What Was Measured
The subject headings attached to it are Blood Glucose, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Glucose Clamp Technique, Hepatocyte Nuclear Factor 1-alpha, Heterozygote and Hypoglycemic Agents.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide) in 10 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2020 (Diabetes), a journal based in United States.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.